Beryl L Manning-Geist

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5055621/publications.pdf

Version: 2024-02-01

1170033 1051228 31 309 9 16 citations g-index h-index papers 31 31 31 335 docs citations citing authors all docs times ranked

#	Article	IF	CITATIONS
1	Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer. Gynecologic Oncology, 2022, 164, 12-17.	0.6	6
2	Patient-reported benefit from proposed interventions to reduce financial toxicity during cancer treatment. Supportive Care in Cancer, 2022, 30, 2713-2721.	1.0	28
3	Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer. Scientific Reports, 2022, 12, 974.	1.6	8
4	Prospective phase II trial of montelukast to treat bronchiolitis obliterans syndrome after hematopoietic cell transplant and investigation into BOS pathogenesis. Transplantation and Cellular Therapy, 2022, , .	0.6	5
5	Assessment of wound perfusion with near-infrared angiography: A prospective feasibility study. Gynecologic Oncology Reports, 2022, 40, 100940.	0.3	1
6	Risk factors for financial toxicity in patients with gynecologic cancer. American Journal of Obstetrics and Gynecology, 2022, 226, 817.e1-817.e9.	0.7	20
7	MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma. Clinical Cancer Research, 2022, 28, 4456-4465.	3.2	25
8	Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series. International Journal of Gynecological Cancer, 2022, , ijgc-2022-003430.	1.2	5
9	Demographic shifts associated with implementation of evidence-based guidelines for ovarian conservation in patients with endometrioid endometrial cancer. International Journal of Gynecological Cancer, 2022, 32, 1141-1146.	1.2	1
10	Outcomes by Race Among Women Referred to an Academic Colposcopy Clinic with a Patient Navigation Program. Journal of Women's Health, 2021, 30, 902-909.	1.5	4
11	Disease Distribution at Presentation Impacts Benefit of IP Chemotherapy Among Patients with Advanced-Stage Ovarian Cancer. Annals of Surgical Oncology, 2021, 28, 6705-6713.	0.7	1
12	Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis. Gynecologic Oncology, 2021, 162, 345-352.	0.6	8
13	Impact of residual disease at interval debulking surgery on platinum resistance and patterns of recurrence for advanced-stage ovarian cancer. International Journal of Gynecological Cancer, 2021, 31, 1341-1347.	1.2	4
14	Diagnosis and management of an endometrial cancer patient with Cowden syndrome. Gynecologic Oncology, 2021, 163, 14-21.	0.6	6
15	Quaternary and beyond cytoreduction: An updated and expanded analysis. Gynecologic Oncology Reports, 2021, 37, 100851.	0.3	1
16	Predictive validity of ACS-NSQIP risk calculator in ovarian cancer patients undergoing interval debulking surgery. Gynecologic Oncology, 2021, 162, S240.	0.6	0
17	Predictive validity of American College of Surgeons: National Surgical Quality Improvement Project risk calculator in patients with ovarian cancer undergoing interval debulking surgery. International Journal of Gynecological Cancer, 2021, 31, 1356-1362.	1.2	3
18	Pre-clinical Stress Management Workshops Increase Medical Students' Knowledge and Self-awareness of Coping with Stress. Medical Science Educator, 2020, 30, 235-241.	0.7	8

#	Article	IF	CITATIONS
19	Use of ablation and ultrasonic aspiration at primary debulking surgery in advanced stage ovarian, fallopian tube, and primary peritoneal cancer. International Journal of Gynecological Cancer, 2020, 30, 1052-1057.	1.2	1
20	Neoadjuvant chemotherapy does not disproportionately influence post-operative complication rates or time to chemotherapy in obese patients with advanced-stage ovarian cancer. Gynecologic Oncology, 2020, 159, 687-691.	0.6	6
21	Trends in Patient Demographics and Diagnostic Yield at an Academic Colposcopy Clinic From 2008 to 2018. Journal of Lower Genital Tract Disease, 2020, 24, 178-183.	0.9	2
22	Validation of algorithms to identify adverse perinatal outcomes in the Medicaid Analytic Extract database. Pharmacoepidemiology and Drug Safety, 2020, 29, 419-426.	0.9	17
23	A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome. American Journal of Obstetrics and Gynecology, 2019, 221, 326.e1-326.e7.	0.7	21
24	Sexual Assault in Ethiopian Contexts: Data From a Large Sample of Women and Girls Presenting at Two Hospital-Based, Limited-Resource Sexual Assault Treatment Clinics. Violence Against Women, 2019, 25, 1074-1095.	1.1	1
25	Tubo-ovarian abscesses in postmenopausal women: Clinical presentation and outcomes. Maturitas, 2019, 125, 20-26.	1.0	9
26	Learning in a High-Stress Clinical Environment: Stressors Associated with Medical Students' Clerkship Training on Labor and Delivery. Teaching and Learning in Medicine, 2019, 31, 385-392.	1.3	7
27	Infection, thrombosis, and oncologic outcome after interval debulking surgery: Does perioperative blood transfusion matter?. Gynecologic Oncology, 2019, 153, 63-67.	0.6	17
28	Pediatric Granular Cell Tumors of the Vulva: A Report of 4 Cases and a Review of the Literature. Journal of Pediatric and Adolescent Gynecology, 2018, 31, 311-314.	0.3	8
29	Moving beyond "complete surgical resection―and "optimal― Is low-volume residual disease another option for primary debulking surgery?. Gynecologic Oncology, 2018, 150, 233-238.	0.6	21
30	Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology, 2017, 147, 250-256.	0.6	33
31	The Impact of Diabetes Mellitus on Wound Healing in Breast Reconstruction. Annals of Plastic Surgery, 2017, 78, 260-263.	0.5	32